Erythroderma in Pityriasis Rubra Pilaris — Treatment After Acitretin or Methotrexate Failure

Clinical Scenario

This protocol addresses erythroderma presenting as a severe manifestation of pityriasis rubra pilaris (PRP). Erythroderma occurs in a subset of PRP cases and requires a structured approach, particularly when initial systemic therapy does not achieve clinical remission.

When the First-Line Approach Did Not Work

First-line management of erythrodermic pityriasis rubra pilaris typically involves acitretin or methotrexate, targeting clinical remission of erythroderma. When that remission is not achieved with these agents, escalation to the next treatment step is indicated — and a different class of systemic therapy is required.

Next-Line Approach (Partial Overview)

The next-line protocol uses a systemic corticosteroid-based strategy. The specific agent selection, regimen structure, and tapering approach are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Exfoliative dermatitis has been related to a severe form of pityriasis rubra pilaris in 1.25% to 8.2% of cases.

Systemic corticosteroids Prednisone 1 mg/kg/24 h, then gradually decreased.

DOI: 10.1016/j.adengl.2018.05.033

View source ↗